Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Darier Disease Drugs Market by Treatment (Medication, Surgery, Others), by Application (Topical Retinoids, Oral Retinoids, Others) and by End User (Hospitals, Homecare, Specialty Clinics, Dermatologist, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A11925

Pages: NA

Charts: NA

Tables: NA

Darier disease, commonly known as keratosis follicularis, is a skin condition that causes warty lesions all over the body triggered by a genetic mutation. It is inherited in an autosomal dominant way and is caused by a mutation in the ATP2A2 gene. Rough bumps (papules) or plaques, which may be greasy or develop a brown or yellow crust on the skin, are among the symptoms of Darier disease. Furthermore, scalp, forehead, upper arms, chest, back, knees, elbows, and behind the ear are the most typical areas for blemishes. Nail abnormalities, such as red and white streaks in the nails with an unusual texture, and small pits in the palms of the hands and soles of the feet, are other signs of the disease.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future, owing to the demand for vaccine and drugs for the treatment of COVID-19. This, in turn, is expected to have a significant impact on the Darier disease drugs market.

Top Impacting Factors

Rise in demand for novel treatment, huge investment on research and development activities to develop novel therapies for Darier disease are some factors boosting market growth of the Darier disease market.

Furthermore, huge financial support to the researchers for developing novel intervention and the emergence of dermatological preparations used to treat complication associated with Darier disease boost the market growth.

In addition, increase in healthcare expenditure, collaborations & partnerships between key players to facilitate drug development, rise in R & D to improve quality of drugs, launches of novel developed drug in market and are some factors which boost the market growth.

According to the U.S. National Library of Medicine, in April 2021, the prevalence of Darier disease is estimated to be 1 in 30,000 people in Scotland, and 1 in 36,000 people in northern England, and 1 in 100,000 people in Denmark. Moreover, rise in population and increase in awareness toward Darier disease act as key drivers of the Darier disease drug market.

Market Trends

New Product Launches to Flourish the Market

In August 2019, Recursion Pharmaceuticals Inc. is conducting pre-clinical trial study for its undisclosed research project. If trial successful, it will open up the possibility of near-term testing of undisclosed research project in patients with Darier disease.

In January 2019, BridgeBio Inc. secured $299.2 million from their principal investors KKR and Viking investors for developing a novel molecule to target genetic disorders in multiple therapeutic areas, including genetic dermatology, oncology, and neurology. This fund will support the existing drug research and development plans and expand the company’s genetic portfolio.

Key Benefits of the Report

  • This study presents the analytical depiction of the Darier disease drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Darier Disease Drugs Market Report

  • Which are the leading players active in the Darier disease drugs market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "Darier disease drugs market"?
  • What is "Darier disease drugs market” prediction in the future?
  • Who are the leading global players in the "Darier disease drugs market"?
  • What are the current trends and predicted trends?
  • What are the key benefits of the “Darier disease drugs market" report? 

Key Market Segments

  • By Treatment
    • Medication
    • Surgery
    • Others
  • By Application
    • Topical Retinoids
    • Oral Retinoids
    • Others
  • By End User
    • Hospitals
    • Homecare
    • Specialty Clinics
    • Dermatologist
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of LAMEA


Key Market Players

  • Nimble Pharmaceuticals
  • Galderma Laboratories L.P.
  • Recursion Pharmaceuticals Inc.
  • Bridge Bio Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Glenmark Pharmaceuticals Inc.
  • Bausch Health
  • ALLERGAN
  • Mayne Pharma Group Limited
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DARIER DISEASE DRUGS MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Medication

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Surgery

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: DARIER DISEASE DRUGS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Topical Retinoids

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Oral Retinoids

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: DARIER DISEASE DRUGS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Homecare

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Specialty Clinics

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Dermatologist

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Others

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: DARIER DISEASE DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Darier Disease Drugs Market

        • 7.2.6.1. Market Size and Forecast, By Treatment
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User
      • 7.2.7. Canada Darier Disease Drugs Market

        • 7.2.7.1. Market Size and Forecast, By Treatment
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User
      • 7.2.8. Mexico Darier Disease Drugs Market

        • 7.2.8.1. Market Size and Forecast, By Treatment
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Darier Disease Drugs Market

        • 7.3.6.1. Market Size and Forecast, By Treatment
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User
      • 7.3.7. Germany Darier Disease Drugs Market

        • 7.3.7.1. Market Size and Forecast, By Treatment
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User
      • 7.3.8. Italy Darier Disease Drugs Market

        • 7.3.8.1. Market Size and Forecast, By Treatment
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User
      • 7.3.9. Spain Darier Disease Drugs Market

        • 7.3.9.1. Market Size and Forecast, By Treatment
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User
      • 7.3.10. UK Darier Disease Drugs Market

        • 7.3.10.1. Market Size and Forecast, By Treatment
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User
      • 7.3.11. Russia Darier Disease Drugs Market

        • 7.3.11.1. Market Size and Forecast, By Treatment
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User
      • 7.3.12. Rest Of Europe Darier Disease Drugs Market

        • 7.3.12.1. Market Size and Forecast, By Treatment
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Darier Disease Drugs Market

        • 7.4.6.1. Market Size and Forecast, By Treatment
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User
      • 7.4.7. Japan Darier Disease Drugs Market

        • 7.4.7.1. Market Size and Forecast, By Treatment
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User
      • 7.4.8. India Darier Disease Drugs Market

        • 7.4.8.1. Market Size and Forecast, By Treatment
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User
      • 7.4.9. South Korea Darier Disease Drugs Market

        • 7.4.9.1. Market Size and Forecast, By Treatment
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User
      • 7.4.10. Australia Darier Disease Drugs Market

        • 7.4.10.1. Market Size and Forecast, By Treatment
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User
      • 7.4.11. Thailand Darier Disease Drugs Market

        • 7.4.11.1. Market Size and Forecast, By Treatment
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User
      • 7.4.12. Malaysia Darier Disease Drugs Market

        • 7.4.12.1. Market Size and Forecast, By Treatment
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User
      • 7.4.13. Indonesia Darier Disease Drugs Market

        • 7.4.13.1. Market Size and Forecast, By Treatment
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User
      • 7.4.14. Rest of Asia Pacific Darier Disease Drugs Market

        • 7.4.14.1. Market Size and Forecast, By Treatment
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Darier Disease Drugs Market

        • 7.5.6.1. Market Size and Forecast, By Treatment
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User
      • 7.5.7. South Africa Darier Disease Drugs Market

        • 7.5.7.1. Market Size and Forecast, By Treatment
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User
      • 7.5.8. Saudi Arabia Darier Disease Drugs Market

        • 7.5.8.1. Market Size and Forecast, By Treatment
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User
      • 7.5.9. UAE Darier Disease Drugs Market

        • 7.5.9.1. Market Size and Forecast, By Treatment
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User
      • 7.5.10. Argentina Darier Disease Drugs Market

        • 7.5.10.1. Market Size and Forecast, By Treatment
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User
      • 7.5.11. Rest of LAMEA Darier Disease Drugs Market

        • 7.5.11.1. Market Size and Forecast, By Treatment
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bridge Bio Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Recursion Pharmaceuticals Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. ALLERGAN

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Novartis AG

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Nimble Pharmaceuticals

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Sun Pharmaceutical Industries Ltd.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Mayne Pharma Group Limited

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Bausch Health

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Galderma Laboratories L.P.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Glenmark Pharmaceuticals Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DARIER DISEASE DRUGS MARKET, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DARIER DISEASE DRUGS MARKET FOR MEDICATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DARIER DISEASE DRUGS MARKET FOR SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DARIER DISEASE DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DARIER DISEASE DRUGS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DARIER DISEASE DRUGS MARKET FOR TOPICAL RETINOIDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DARIER DISEASE DRUGS MARKET FOR ORAL RETINOIDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DARIER DISEASE DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DARIER DISEASE DRUGS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DARIER DISEASE DRUGS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL DARIER DISEASE DRUGS MARKET FOR HOMECARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL DARIER DISEASE DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL DARIER DISEASE DRUGS MARKET FOR DERMATOLOGIST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL DARIER DISEASE DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL DARIER DISEASE DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA DARIER DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. U.S. DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 21. U.S. DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. CANADA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 24. CANADA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE DARIER DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ITALY DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 40. ITALY DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. UK DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 46. UK DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. UK DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DARIER DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. CHINA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 59. CHINA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. INDIA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 65. INDIA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA DARIER DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. UAE DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 99. UAE DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA DARIER DISEASE DRUGS, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA DARIER DISEASE DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA DARIER DISEASE DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. BRIDGE BIO INC.: KEY EXECUTIVES
  • TABLE 108. BRIDGE BIO INC.: COMPANY SNAPSHOT
  • TABLE 109. BRIDGE BIO INC.: OPERATING SEGMENTS
  • TABLE 110. BRIDGE BIO INC.: PRODUCT PORTFOLIO
  • TABLE 111. BRIDGE BIO INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. RECURSION PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 113. RECURSION PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 114. RECURSION PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 115. RECURSION PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 116. RECURSION PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. ALLERGAN: KEY EXECUTIVES
  • TABLE 118. ALLERGAN: COMPANY SNAPSHOT
  • TABLE 119. ALLERGAN: OPERATING SEGMENTS
  • TABLE 120. ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 121. ALLERGAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 123. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 124. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 125. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 126. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. NIMBLE PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 128. NIMBLE PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 129. NIMBLE PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 130. NIMBLE PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 131. NIMBLE PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 133. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 134. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 135. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 136. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. MAYNE PHARMA GROUP LIMITED: KEY EXECUTIVES
  • TABLE 138. MAYNE PHARMA GROUP LIMITED: COMPANY SNAPSHOT
  • TABLE 139. MAYNE PHARMA GROUP LIMITED: OPERATING SEGMENTS
  • TABLE 140. MAYNE PHARMA GROUP LIMITED: PRODUCT PORTFOLIO
  • TABLE 141. MAYNE PHARMA GROUP LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. BAUSCH HEALTH: KEY EXECUTIVES
  • TABLE 143. BAUSCH HEALTH: COMPANY SNAPSHOT
  • TABLE 144. BAUSCH HEALTH: OPERATING SEGMENTS
  • TABLE 145. BAUSCH HEALTH: PRODUCT PORTFOLIO
  • TABLE 146. BAUSCH HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. GALDERMA LABORATORIES L.P.: KEY EXECUTIVES
  • TABLE 148. GALDERMA LABORATORIES L.P.: COMPANY SNAPSHOT
  • TABLE 149. GALDERMA LABORATORIES L.P.: OPERATING SEGMENTS
  • TABLE 150. GALDERMA LABORATORIES L.P.: PRODUCT PORTFOLIO
  • TABLE 151. GALDERMA LABORATORIES L.P.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. GLENMARK PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 153. GLENMARK PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 154. GLENMARK PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 155. GLENMARK PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 156. GLENMARK PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DARIER DISEASE DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DARIER DISEASE DRUGS MARKET
  • FIGURE 3. SEGMENTATION DARIER DISEASE DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DARIER DISEASE DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDARIER DISEASE DRUGS MARKET
  • FIGURE 11. DARIER DISEASE DRUGS MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. DARIER DISEASE DRUGS MARKET FOR MEDICATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DARIER DISEASE DRUGS MARKET FOR SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DARIER DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. DARIER DISEASE DRUGS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 16. DARIER DISEASE DRUGS MARKET FOR TOPICAL RETINOIDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DARIER DISEASE DRUGS MARKET FOR ORAL RETINOIDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. DARIER DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. DARIER DISEASE DRUGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. DARIER DISEASE DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. DARIER DISEASE DRUGS MARKET FOR HOMECARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. DARIER DISEASE DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. DARIER DISEASE DRUGS MARKET FOR DERMATOLOGIST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. DARIER DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: DARIER DISEASE DRUGS MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. BRIDGE BIO INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. BRIDGE BIO INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. BRIDGE BIO INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. RECURSION PHARMACEUTICALS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. RECURSION PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. RECURSION PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. ALLERGAN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. ALLERGAN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. ALLERGAN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. NIMBLE PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. NIMBLE PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. NIMBLE PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. MAYNE PHARMA GROUP LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. MAYNE PHARMA GROUP LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. MAYNE PHARMA GROUP LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. BAUSCH HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. BAUSCH HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. BAUSCH HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. GALDERMA LABORATORIES L.P.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. GALDERMA LABORATORIES L.P.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. GALDERMA LABORATORIES L.P.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. GLENMARK PHARMACEUTICALS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. GLENMARK PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. GLENMARK PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Darier Disease Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue